Substituted glycinamides



Patented Sept. 26, 1950 UNITED STATES PATENT OFFICE 2,523,275 V SUBSTITUTED cLYc'INAMmEs William F. Bruce, Havertown, and Joseph Seifter,

Willow Grove, Pa., assignors to -Wyeth Incorporated, Philadelphia, Pa., a corporation of Delaware Claims.

, This invention relates to new substituted glycinamides having the general formula It has been observed by some workers that a small number of glycinamide derivatives evidence some local anesthetic action although a sys tematic study of the pharmacological actions of substituted clycinamides had never been reported.

We have found, in the preparation and thorough study of a great number of new substituted glycinamides, that a relatively large number of these substituted glycinamides evidence marked pharmacological actions hitherto unsuspected in the art and which we consider to be highly useful in the medicinal field. Specifically, we have found that when particular amines are used in the preparation of the compounds of our inven tion, glycinamide products evidence useful pharmacological action, more specifically described below. w

The new compounds of this invention have the general formula as indicated above where R1 may be a higher alkyl ranging from 5 to 9 carbon atoms, while R2 maybe an alkyl ranging from 1 to 9 carbon atoms, or an aralkyl radical having an alkyl chain of 2' to 5 carbon atoms.

I distilling off the latter under low pressuresi In general, a molar ratio of chloride to amine of about lr2-is preferred for the reaction.

The reaction of the appropriate chloroacetamide and the appropriate primary amine to form the desired substituted glycinamide is preferably operated with a molar ratio, amide to amine of about 1:1 and is carried out in the pres-. ence of a solvent for the reactants such as higher alcohols having four to sevenv carbon atoms in the molecule, dioxane or hydrocarbon solvents, for example, xylene. The reaction is carried out also in the presence of an acid acceptor or mildly basic material such as alkali or alkaline earth metal carbonates, sodium bicarbonate or alkali metal alcoholates, and preferably about 2 to 3 mols of this material is used. The reaction operation is set up for refluxing and the temperature' is the refluxing temperature of the particular solvent selected. Generally, a period of about 10-15 hours is sufiicient for complete reaction. In-the event that solids are formed, these are removed by filtration, the product remaining in solution in the solvent, The solvent is then removed by distillation at low pressures to obtain H the substituted glycinamide product.

It is to be further noted that R1 and R2 may be similar radicals, as for example, where R1 and R2 are both alkyls and contain the same number of carbon atoms having the same structural relation; or R1 and R2 may be dissimilar radicals, for example, where R1 is a higher alkyl and R2 is an aralkyl of the type above-mentioned.

In general, the compounds of the invention may be synthesized by reacting an appropriate chloroacetamide corresponding to the formula with an appropriate primary amine corresponding to the formula where R1 and R2 have the same meaning as inamines.

The new compounds have valuable properties and are useful in that they possess at least one of the following actions: local anesthetic, pressor, spasmolytic, analgesic, sedative and convulsant action.

' It is known that certain amines possess a vasoconstrictor action and are identified as pressor amines, represented by the above-mentioned RiNHz or Rz-NI-Iz amines, are used as intermediates informing the new compounds, and particularly when R1NH2 is a pressor amine, the new products possess pronounced physiological action. When both amines are pressor amines, even greater physiological action in the new compounds has been noted. Thus in substituted glycinamides corresponding to the formula RINHCHZCONHRZ when a pressor amine has been combined, and

particularly on the amino side (left-hand side) of the molecule, the compounds possess very con- 'siderable anesthetic action and in some cases anesthetic action of a high order combined with pressor action. While certain pressor amines may themselves possess a certain small amount of local anesthetic action, a Surprising increase As an important feature of the inven- .tion, it has been discovered that when pressor that when the radicals RlNH and/or NHZRz are the residues of primary pressor amines, a critically new physiological action is found that is different from the physiological action of the 1 primary pressor amines alone. As an example, when the primary pressor amine, l-methylhex-yl amine is condensed with N-alpha-chloroaceto-lmethylhexyl amine, it has been found that the 4 mm. The yield of N-alpha-chloroaceto-l-methylhexyl amine was 30 grams.

A solution of grams of N-alpha-chloroacetol-methylhexyl amine and 5.7 grams of 1-methyl- 1hexyl amine,-'together with 5 grams of sodium carbonate, in 25 cc. of n-butanol was refluxed for 12 hours. The organic layer was washed with water until the washings were free of halogen. It-was then dried, concentrated in vacuo and distilled. The product, alpha-l-rnethylhexyl- :ami'no -Nd-methylhexyl acetamide boiled from 180-l85 C. at a pressure of 4 mm. and from '148'151 C. at 0.5 mm. The yield of colorless, viscous oil was 13 grams.

primary pressor amine residue. ,15

onacmhcmomk Analysis 11/ Carbon Hydrogen Nitrogen imparts to the glycinamide enhanced local anv esthetic action far superior to thevanesthetic ac- $3335 3???.iidt fifjiii 36:33 i332; i312? tion of l-methylhexyl amine itself. Moreover, thi enhanced action is noted when either R 1'NH or NHRz is a primary pressor amine residue, EXAMPLE 11 particularly in the case where RiNHis the primary pressor amine residue, and more particularly when both are primary pressor amine residues. It should be pointed out, however, that the use of primary pressor amines is not invariably necessary in'order to obtain the substituted glycinamides of our invention having highly useful physiological properties.

Certain of the .compounds of the invention have been found also to possess not only arlocal anesthetic action superior to cocaine, but also a spasmolytic or anti-spasmodic action, while. at

the same time having a toxicity considerably below thatof cocaine. V I

The following table illustrates the physiological action of a number of representative compounds when compared to the action of cocaine as a local anesthetic and papaverine as a spasmolytic.

Preparation of alpha-1-methyZhe:cyZamin0-N (-1- methyl-Z-phenylethyl) acetamide For the preparation of the appropriate chloroacetamide intermediate, a solution of 27 grams of amphetamine in 80 cc. of benzene was added in-portions to a solution of 11.3 grams of chloracetyl chloride in benzene. 'I-Ieat :Was evolved and the addition was done at a rate which kept the temperature between and C. On standing, solid amphetamine hydrochloride precipitated and was collected on a filter. This'weighed 13.5 grams and melted at 149 C. The filtrate after removal of the solvent in vacuo gave a yellow oil which solidified on standing. It weighed 26 grams and meltedat68 C. It was moderately soluble in cold ethanol and ethyl ntest ne) Potency I V Toxicity, 'LD 50 in a/K Cocaine Pap-avenue I 1th i i t (Rabbit so a a 19 Subcuta- Intraperi- Cornea) (Rabbit neous toneal n. .W. .a u 1 Cocaine V Papaverine a-l-methylhexylamino-N-l-methy ta a-l-methylhexylamino-N-(l-methyl-Z-phenylethyl) acetamide manor- Proceeding to a better understanding .of this invention, illustrative specific procedures for the preparation of representative compounds fall in within the g n ral formul are set forth in the following examples.

EXAMPLE I methylhezcyl acetamide In order to first prepare the chloroacetamide intermediate, 46 grams of l-methylhexyl amine was added slowly with stirring to a solution of 70 22.6 grams of chloroacetyl chloride in cc. of benzene. After the solution had cooled, no precipitate of the hydrochloride salt appeared. The solution was concentrated and distilled at a temperature of l13-115' 0.; under a vacuum of'3 7-5 acetate and readily soluble in chloroform. It was crystallized from ethyl acetate with the addition of etroleum ether Th r c y t lli d pr duct. N alpha chloroacetoamphetamine melted at 7172 C. Analysis showed 6.0% N (calcd. 6.6%). A sample on distillation boiled at -165 C.

5 31133-111111. Preparation of alpha-'1-met7tylhea:yZammo-N-1- The Analysis Carbon Hydrogen Nitrogen Calculated for O H NnO 74. 46 10. 42 9. 65 Found 74. 54 10.55 9. 67

By procedures analogues to those described in the above examples, the appropriate primary amine, R1NH2, preferably a pressor amine and the appropriate chloracetamide corresponding to the formula ClCI-IzCONHRz 10. alpha-l-methylbutylamino-N 1 methylbutyl acetamide.

11. alpha 1,4 dimethylpentylamino N diphenylmethyl acetamide.

Substantially all of the products of the invention are high boiling basic liquids of limited solubility. It is contemplated within the scope of this invention that while the products may be used in their basic form, they may also be prepared and used in the well-known manner in the form of their acid-addition salts. The preparation of such a salt is Well-known and generally involves the addition of the selected acid to an ether, alcohol or water solution of the basic product. The acid is chosen to yield a salt which is known to those skilled in the art as being physiologically non-toxic. As examples, the hydrochloride, sulfate or acetate salts of the new products may be used.

It is further contemplated that those substituted glycinamides, or the non-toxic salts there-' of, which are less soluble in dilute acid than 0.5% by weight, may be brought into satisfactory solution by the use of solubilizing, surface-active, emulsifying or detergent agents in order to obtain a more complete physiological effect of the specific substituted glycinamide. Lipoid solvents having a physiologically non-toxic effect such as long chain fatty acid partial esters of hexitol anhydrides or oxyalkylene derivatives thereof, vegetable and animal oils and ointment bases such as petroleum jelly or cholesterol are examples of solvents that are considered useful in admixture with the substituted glycinamides for'obtaining an enhanced physiological efiect.

Many modifications of the invention will be apparent to those skilled in the art without departure therefrom or from the scope of the claims, and since the foregoing disclosure has been given by Way of example for clearness and understanding, only, no unnecessary limitations should be understood and the appended claims should be construed as broadly as the state of the art permits.

This application is a division of application Serial No. 668,786, filed May 10, 1946 now Patent No. 2,449,638, dated September 21, 1948.

We claim:

1. New compounds selected from the group consisting of substituted 'glycinamides, corresponding to-the formula RiNHCHzCONHRz wherein R1 is a branched chain alkyl having 5 to 9 carbon atoms and R2 is a member of the group consisting of an alkyl and an aralkyl having alkyl chains of 2 to 5 carbon atoms and a single isocyclic group; and the non-toxic salts of said substituted glycinamides.

2. Substituted glycinamides. corresponding to the formula RiNHCHzCONHRz where R1 is a branched chain alkyl having 5 to 9 carbon atoms and R2 is an alkyl radical.

3. Substituted glycinamides; corresponding to the formula REFERENCES CITED The following references are of record in the file of this patent:

UNITED STATES PATENTS Number Name Date 2,139,190 Iselin et al. Dec. 6, 1938 2,328,021 Katzman et al Aug. 31, 1943 2,411,662 Martin et a1 Nov. 26 1946 OTHER REFERENCES Braun et al. Ber. Deut. Chem., vol. 60 (1927), page 354.

Braun et al. Ber. Deut. Chem. vol. 62 (1929) pages 2766-2776. 

1. NEW COMPOUNDS SELECTED FROM THE GROUP CONSISTING OF SUBSITUTED GIYCINAMIDES, CORRESPONDING TO THE FORMULA. @SP R1NHCH2CONHR2 @SP WHEREIN R1 IS A BRANCHED CHAIN ALKYL HAVING 5 TO 9 CARBON ATOMS AND R2 IS A MEMBER OF THE GROUP CONSISTING OF AN ALKYL AND AN ARALKYL HAVING ALKYL CHAINS OF 2 TO 5 CARBON ATOMS AND A SINGLE ISOCYCLIC GROUP; AND THE NON-TOXIC SALTS OF SAID SUBSTITUTED GLYCINAMIDES.
 5. THE NEW COMPOUND, ALPHA-1-METHYLHEXYL AMINO-N-(1-METHYL-2-PHENYIETHYL) ACETAMIDE. 